By a News Reporter-Staff News Editor at Gastroenterology Week -- Research findings on Lung Cancer are discussed in a new report. According to news reporting originating in Kyoto, Japan, by NewsRx journalists, research stated, "A study of patients with advanced non-squamous non-small cell lung cancer (NSCLC) evaluated epidermal growth factor receptor (EGFR) mutation status and serum hepatocyte growth factor (HGF) for their associations with response to gefitinib therapy and prognostic impact. An enzyme-linked immunosorbent assay was used to determine levels of HGF in serum from 96 Japanese patients with advanced non-squamous NSCLC."
The news reporters obtained a quote from the research from Kyoto University, "The peptic nucleic acid-locked nucleic acid clamp method was used to determine their EGFR somatic mutation status. We evaluated the relationship between each independent clinicopathological variable and the response to gefitinib therapy and risk factors associated with prognosis. HGF-positive serum status (hazard ratio, 1.536; 95% confidence interval, 1.042-2.400; p=0.0295) had a significant and independent negative effect on progression-free survival among patients with wild-type EGFR."
According to the news reporters, the research concluded: "We demonstrate that having HGF-positive serum is predictive of a negative response to gefitinib therapy in patients with advanced NSCLC who harbor wild-type EGFR."
For more information on this research see: Clinical significance of serum hepatocyte growth factor and epidermal growth factor gene somatic mutations in patients with non-squamous non-small cell lung cancer receiving gefitinib or erlotinib. Medical Oncology, 2012;29(3):1614-21. Medical Oncology can be contacted at: Springer, 233 Spring Street, New York, NY 10013, USA. (Springer - www.springer.com; Medical Oncology - www.springerlink.com/content/1357-0560/)
Our news correspondents report that additional information may be obtained by contacting K. Masago, Dept. of Respiratory Medicine, Graduate School of Medicine, Kyoto University, 54 Shogoin-Kawaracho, Sakyo-ku, Kyoto 606-8507, Japan (see also Lung Cancer).
The publisher of the journal Medical Oncology can be contacted at: Springer, 233 Spring Street, New York, NY 10013, USA.
Keywords for this news article include: Asia, Kyoto, Japan, Therapy, Genetics, Oncology, Cytokines, Lung Neoplasms, Protein Kinases, Epithelial Cells, Gastroenterology, Membrane Proteins, Phosphotransferases, Hepatocyte Growth Factor, Non Small Cell Lung Cancer, Epidermal Growth Factor Receptor, Receptor Protein Tyrosine Kinases.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC
To see more of the NewsRx.com, or to subscribe, go to http://www.newsrx.com .